Skip to main content
  • Researchers Halt Co-STAR Trial Due to Colchicine’s Heightened Stroke Risk Post-TAVR

    While colchicine shows promise in mitigating inflammation-driven complications after transcatheter aortic valve replacement (TAVR), researchers in the Co-STAR trial urge a “cautious, tailored approach” to its use due to associated stroke risks. 

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details